PF 3654764

Drug Profile

PF 3654764

Alternative Names: PF-03654764

Latest Information Update: 29 Sep 2010

Price : $50

At a glance

  • Originator Pfizer
  • Class Neuropsychotherapeutics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic rhinitis; Alzheimer's disease

Most Recent Events

  • 27 Sep 2010 Discontinued - Phase-I for Alzheimer's disease in Singapore (PO)
  • 27 Sep 2010 Discontinued - Phase-II for Allergic rhinitis in Canada (PO)
  • 31 May 2010 Pfizer completes a phase II trial in Allergic rhinitis in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top